Phase I
Janssen discontinued the development partnership due to advancements made by other companies against the human papillomavirus and its own changing strategic priorities.
LogicBio Therapeutics has received the green light to continue dosing participants in its Phase I/II Sunrise trial, following a clinical hold placed by the FDA due to adverse events in pediatric patients.
Athira Pharma announced the duration of its open-label study of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s Disease (AD) has been increased from six months to eighteen months.
BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.
Complicated bone fractures take a long while to heal. Bone Therapeutics S.A. is developing a cell therapy product that speeds bone regeneration and just may solve that problem.
Pfizer’s Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
Intellia’s first-quarter financial conference call and report focused on the ongoing Phase I trial of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy patients.
After the market closed on Wednesday, Allogene reported its first-quarter financial results, along with updates to its research programs. The report marked Allogene’s fourth anniversary.
Awakn researches and develops drug-assisted psychotherapy treatments, focusing on psychedelic drugs to treat addiction.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES